Thomas Botta, MD
Pulmonary Disease · Danbury, CTNPI 1417177072
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $196 of the $259 with a category attached, or 75.7%. 10 manufacturers reported payments, led by Sanofi-aventis U.S. LLC at 24.3% of the total. Reporting peaked in 2023 at $137 and has fallen 84.8% since, to $21 in 2024. That places this record below the midpoint for pulmonary disease clinicians in CT, where the typical reported total is $1,017.
Across 12 payments — averaging $21.56 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sanofi-aventis U.S. LLC$63
- GSK$42
- Takeda Pharmaceuticals U.S.A., Inc.$24
- Neurelis, Inc.$21
- Pfizer$21
- Bristol Myers Squibb$20
- plus $69 from 4 others
Across 4 payments — averaging $3094.17 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Boehringer Ingelheim$12K
What the payments were for
- Food & beverage$19676%
- Education$6324%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Sanofi-aventis U.S. LLC | 1 | $63 |
| GSK | 2 | $42 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $24 |
| Neurelis, Inc. | 1 | $21 |
| Pfizer | 1 | $21 |
| Bristol Myers Squibb | 1 | $20 |
| Sanofi | 1 | $19 |
| E.r. Squibb & Sons, L.L.C. | 1 | $18 |
| Seagen Inc. | 1 | $18 |
| Johnson & Johnson | 1 | $13 |
How this compares
$259 in reported general payments places this provider in the 25th percentile of 255 pulmonary disease providers in Connecticut.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OfevNintedanib Esylate | 25 | $327,737 |
| Dupixent PenDupilumab | 33 | $137,970 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 99 | $105,638 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 32 | $28,108 |
| Breo ElliptaFluticasone/Vilanterol | 48 | $25,333 |
| Spiriva RespimatTiotropium Bromide | 13 | $15,720 |
| Arnuity ElliptaFluticasone Furoate | 24 | $11,524 |
| Incruse ElliptaUmeclidinium Bromide | 14 | $7,939 |
| DuleraMometasone/Formoterol | 11 | $6,505 |
| SymbicortBudesonide/Formoterol Fumarate | 16 | $6,321 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 12 | $4,854 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 64 | $3,260 |
| Wixela InhubFluticasone Propion/Salmeterol | 21 | $2,546 |
| Ventolin HfaAlbuterol Sulfate | 14 | $1,373 |
| Azithromycin | 36 | $717 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta, Arnuity Ellipta, Incruse Ellipta | $42 | $178,542217 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 25th percentile of 255 pulmonary disease providers in Connecticut.
Other pulmonary disease in Danbury
- Geoffrey ChuppNew Haven$1.2M
- Tapas BandyopadhyayWest Hartford$483K
- Raj ParikhHartford$386K
- Patrick TroyHartford$385K
- Michael ImevboreNew Haven$323K
- Jeffrey NascimentoHartford$213K
- Thinesh DahanayakeNorwich$192K
- Naftali KaminskiNew Haven$180K
- Daniel GerardiHartford$156K
- Roman SpivakAnsonia$140K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.